logo

Europe Autoimmune Disease Diagnostics Market Size (2024 - 2029)

The Europe Autoimmune Disease Diagnostics Market is projected to experience growth due to factors such as the rising prevalence of autoimmune disorders, increased public awareness, and advancements in technology and laboratory automation. The market's expansion is driven by the need for early diagnosis and treatment to prevent severe outcomes in conditions like multiple sclerosis, rheumatoid arthritis, and psoriasis. Efforts by the European Commission to enhance public awareness about autoimmune disease risk factors further contribute to the market's growth, as individuals are encouraged to seek timely diagnosis and treatment.

Home Market Analysis Healthcare Research Medical Devices Research Diagnostic Devices Research Clinical Diagnostic Devices Research Clinical Diagnostic Laboratory Equipment Research Disease Specific Diagnostic Devices Research Immune System Diagnostics Research Europe Autoimmune Disease Diagnostics Market Market Size

Market Size of Europe Autoimmune Disease Diagnostics Industry

Europe Autoimmune Disease Diagnostics Market Size
Study Period 2019 - 2029
Base Year For Estimation 2023
Market Size (2024) USD 1.38 Billion
Market Size (2029) USD 1.82 Billion
CAGR (2024 - 2029) 5.69 %
Market Concentration Medium

Major Players

Europe Autoimmune Disease Diagnostics Market Key Players

*Disclaimer: Major Players sorted in no particular order

Europe Autoimmune Disease Diagnostics Market Analysis

The Europe Autoimmune Disease Diagnostics Market size is estimated at USD 1.38 billion in 2024, and is expected to reach USD 1.82 billion by 2029, growing at a CAGR of 5.69% during the forecast period (2024-2029).

The major factors driving the market are the increasing prevalence, along with the rising public awareness, technological advancements, and improved laboratory automation.

European countries are being confronted with an increase in the occurrence of the most autoimmune immune disorders. The prevalence rate of multiple sclerosis in Europe is estimated at 83 out of 100,000. Moreover, multiple sclerosis is more common among women than men. In addition, two million people are affected by rheumatoid arthritis and nearly 2-3% of the population is estimated to be affected by psoriasis, which is one of the most common forms of autoimmune diseases. Owing to the aforementioned conditions, early diagnosis and onset of treatment can make a significant difference in preventing permanent damage and disability. Results of autoimmune disease diagnostic tests can confirm a disorder, estimate disease severity, aid in assessing prognosis. They are also useful to follow disease activity.

The increasing awareness of auto-immune diseases, through programs of research, education, support, and advocacy is a key factor augmenting the usage rates. The European Commission is taking several steps to increase awareness among the public regarding the risk factors in developing autoimmune diseases. Thus, as symptoms occur, they can seek diagnosis and begin a treatment regimen.

Europe Autoimmune Disease Diagnostics Industry Segmentation

An autoimmune disease is a condition that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune diseases.

By Disease Type
Systemic Autoimmune Disease
Rheumatoid Arthritis
Psoriasis
Systemic Lupus Erythematosus (SLE)
Multiple Sclerosis
Other Systemic Autoimmune Diseases
Localized Autoimmune Disease
Inflammatory Bowel Disease
Type-1 Diabetes
Thyroid
Other Localized Autoimmune Diseases
By Diagnostic Technique
Immunofluorescence Assays (IFA)
Enzyme-linked Immunosorbant Assay (ELISA)
Western Blotting
Multiplex Immunoassay
Agglutination
Other Diagnostic Techniques
Geography
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region Or Segment?
Customize Now

Europe Autoimmune Disease Diagnostics Market Size Summary

The European autoimmune disease diagnostics market is poised for significant growth, driven by an increasing prevalence of autoimmune disorders and heightened public awareness. Technological advancements and improved laboratory automation are further propelling the market forward. The region is witnessing a rise in conditions such as multiple sclerosis, rheumatoid arthritis, and psoriasis, necessitating early diagnosis and treatment to prevent permanent damage. Diagnostic tests play a crucial role in confirming disorders, estimating severity, and assessing prognosis, thereby aiding in the management of these diseases. The European Commission's efforts to raise awareness about risk factors are encouraging individuals to seek timely diagnoses and initiate treatment regimens.

The market is characterized by a moderate level of competition, with established players like Abbott Laboratories, bioMérieux, Bio-Rad Laboratories, and Thermo Fisher Scientific Inc. leading the charge. The availability of treatment options, such as biologics, and the presence of reimbursement schemes are contributing to the growth of the rheumatoid arthritis segment. The demand for rheumatoid arthritis diagnostics is expected to rise due to the increasing incidence of the disease and the focus on high specificity and sensitivity of diagnostic kits. Additionally, favorable regulatory guidelines for rapid diagnostic kits are anticipated to further stimulate market expansion. New entrants are also emerging, aiming to capitalize on the growing demand for autoimmune disease diagnostics in Europe.

Explore More

Europe Autoimmune Disease Diagnostics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence and Rising Public Awareness

      2. 1.2.2 Technological Advancements and Improved Laboratory Automation

    3. 1.3 Market Restraints

      1. 1.3.1 Slow Turnaround Time of Results and Need of Multiple Diagnostic Test

      2. 1.3.2 High Cost

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Disease Type

      1. 2.1.1 Systemic Autoimmune Disease

        1. 2.1.1.1 Rheumatoid Arthritis

        2. 2.1.1.2 Psoriasis

        3. 2.1.1.3 Systemic Lupus Erythematosus (SLE)

        4. 2.1.1.4 Multiple Sclerosis

        5. 2.1.1.5 Other Systemic Autoimmune Diseases

      2. 2.1.2 Localized Autoimmune Disease

        1. 2.1.2.1 Inflammatory Bowel Disease

        2. 2.1.2.2 Type-1 Diabetes

        3. 2.1.2.3 Thyroid

        4. 2.1.2.4 Other Localized Autoimmune Diseases

    2. 2.2 By Diagnostic Technique

      1. 2.2.1 Immunofluorescence Assays (IFA)

      2. 2.2.2 Enzyme-linked Immunosorbant Assay (ELISA)

      3. 2.2.3 Western Blotting

      4. 2.2.4 Multiplex Immunoassay

      5. 2.2.5 Agglutination

      6. 2.2.6 Other Diagnostic Techniques

    3. 2.3 Geography

      1. 2.3.1 Europe

        1. 2.3.1.1 Germany

        2. 2.3.1.2 United Kingdom

        3. 2.3.1.3 France

        4. 2.3.1.4 Italy

        5. 2.3.1.5 Spain

        6. 2.3.1.6 Rest of Europe

Europe Autoimmune Disease Diagnostics Market Size FAQs

The Europe Autoimmune Disease Diagnostics Market size is expected to reach USD 1.38 billion in 2024 and grow at a CAGR of 5.69% to reach USD 1.82 billion by 2029.

In 2024, the Europe Autoimmune Disease Diagnostics Market size is expected to reach USD 1.38 billion.

Europe Autoimmune Disease Diagnostics Market Report Snapshots

Europe Autoimmune Disease Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)